174 related articles for article (PubMed ID: 31362665)
1. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer.
Bearz A; Cecco S; Francescon S; Re FL; Corona G; Baldo P
Recent Pat Anticancer Drug Discov; 2019; 14(3):242-257. PubMed ID: 31362665
[TBL] [Abstract][Full Text] [Related]
2. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.
Basile D; Lisanti C; Pizzichetta MA; Baldo P; Fornasier G; Lo Re F; Corona G; Puglisi F
Recent Pat Anticancer Drug Discov; 2019; 14(3):203-225. PubMed ID: 31362664
[TBL] [Abstract][Full Text] [Related]
3. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.
Vaccher E; Schioppa O; Martellotta F; Fornasier G; Giacomin E; Re FL; Baldo P; Corona G; Gobitti C
Recent Pat Anticancer Drug Discov; 2019; 14(3):226-241. PubMed ID: 31362663
[TBL] [Abstract][Full Text] [Related]
4. Safety Profiles and Pharmacovigilance Considerations for Recently Patented / Approved Anticancer Drugs.
Baldo P
Recent Pat Anticancer Drug Discov; 2019; 14(3):202. PubMed ID: 31778105
[No Abstract] [Full Text] [Related]
5. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC; Riely GJ
JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
7. [New biological treatments for lung cancer].
Zalcman G; Richard N; Bergot E
Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
[TBL] [Abstract][Full Text] [Related]
8. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.
Mackey JR; Kerbel RS; Gelmon KA; McLeod DM; Chia SK; Rayson D; Verma S; Collins LL; Paterson AH; Robidoux A; Pritchard KI
Cancer Treat Rev; 2012 Oct; 38(6):673-88. PubMed ID: 22365657
[TBL] [Abstract][Full Text] [Related]
9. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
10. Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations.
Kuykendall A; Chiappori A
Cancer Control; 2014 Jan; 21(1):67-73. PubMed ID: 24357744
[TBL] [Abstract][Full Text] [Related]
11. EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
De Mello RA; Liu DJ; Aguiar PN; Tadokoro H
Recent Pat Anticancer Drug Discov; 2016; 11(4):393-400. PubMed ID: 27491402
[TBL] [Abstract][Full Text] [Related]
12. [Targeted therapies and radiation therapy in non-small cell lung cancer].
Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
[TBL] [Abstract][Full Text] [Related]
13. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies for lung cancer: clinical experience and novel agents.
Larsen JE; Cascone T; Gerber DE; Heymach JV; Minna JD
Cancer J; 2011; 17(6):512-27. PubMed ID: 22157296
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
17. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
18. EGFR-directed therapies to treat non-small-cell lung cancer.
Ho C; Laskin J
Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
[TBL] [Abstract][Full Text] [Related]
19. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.
Stinchcombe TE
Curr Treat Options Oncol; 2016 Apr; 17(4):18. PubMed ID: 26961971
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Kazandjian D; Blumenthal GM; Yuan W; He K; Keegan P; Pazdur R
Clin Cancer Res; 2016 Mar; 22(6):1307-12. PubMed ID: 26980062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
